Drug news
FDA approves Zubsolv (Orexo) for treatment of Opioid Dependence
The FDA has approved sublingual Zubsolv (buprenorphine/naloxone), from Orexo, as maintenance treatment for people suffering from Opioid Dependence.
Studies indicate that Zubsolv was preferred by more than 8 out of 10 of the participants on all acceptance parameters tested: overall acceptability, taste masking, after taste experience, mouth-feel, and ease of administration. The study also confirmed a fast dissolve time. The product will be launched in September.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins